Harvard Apparatus Regenerative Technology Inc. HRGN
Set alert
At close · Oct 30
- YTD
- +25.00%
- 1 year
- +19.17%
- Open
- 2.24
- Prev close
- 2.16
- Mkt cap
- 46.65M
- Vol
- 1.80K
- Avg vol
- 1.61K
- EPS
- -0.39
- P/E
- 0.00
More statistics
- Low
- 2.23
- High
- 2.30
News
6 months ago globenewswire.com
Harvard Apparatus Regenerative Technology Announces First Patient Treated with Cellspan Esophageal Implant at Mayo Clinic
Holliston, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
9 months ago globenewswire.com
Harvard Apparatus Regenerative Technology Collaborates with University of Southern California to Test Treatment for Esophageal Disease
HOLLISTON, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
11 months ago defenseworld.net
Critical Comparison: Arch Therapeutics (OTCMKTS:ARTH) vs. Biostage (OTCMKTS:BSTG)
Arch Therapeutics (OTCMKTS:ARTH - Get Free Report) and Biostage (OTCMKTS:BSTG - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two…
2 years ago globenewswire.com
Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children's Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia
Holliston, MA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com
Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors
Holliston, MA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com
Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial
Holliston, MA, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com
Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights
Holliston, MA, May 13, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com
Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Holliston, MA, April 02, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com
Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com
Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus
Holliston, MA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com
Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results
Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage…
2 years ago globenewswire.com
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q3 2023 Results
HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc . (OTCQB: HRGN) (“HRGN” or the “Company”), a clinical-stage biotechnology company developing the…
3 years ago prnewswire.com
Activated University of Michigan as The Second Site for Clinical Trial in Severe Esophageal Disease
HOLLISTON, Mass. , Aug. 28, 2023 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("Harvard Apparatus Regenerative Technology" or the "Company"), a clinical-stage…
3 years ago prnewswire.com
Approval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines Agency
HOLLISTON, Mass. , Aug. 21, 2023 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("Harvard Apparatus Regenerative Technology" or the "Company"), a clinical-stage…
3 years ago prnewswire.com
Harvard Apparatus Regenerative Technology Reports Second Quarter 2023 Financial Results
HOLLISTON, Mass. , Aug. 14, 2023 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("Harvard Apparatus Regenerative Technology" or the "Company"), a clinical-stage…
3 years ago prnewswire.com
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q2 2023 Results
HOLLISTON, Mass. , Aug. 9, 2023 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("HRGN" or the "Company"), a clinical-stage biotechnology company developing the…
3 years ago prnewswire.com
Biostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal Disease
HOLLISTON, Mass. , July 18, 2023 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing the technology to regenerate organs…
3 years ago prnewswire.com
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
IQVIA was selected because of its dedicated gastrointestinal team and depth of experience in running cell-therapy clinical trials. HOLLISTON, Mass.
3 years ago seekingalpha.com
Biostage, Inc. (BSTG) Q3 2022 Earnings Call Transcript
Biostage, Inc. (OTC:BSTG) Q3 2022 Earnings Conference Call November 15, 2022 9:00 AM ET Company Participants David Green - Interim Chief Executive Officer Joe Damasio - Chief Financial Officer…